COMMUNIQUÉS West-GlobeNewswire

FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food
22/07/2026
Silver Spring, MD, July 22, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader efforts to Make [...]
RAMSAY SANTE : communiqué de presse - refinancement et prochaines étapes
22/07/2026
COMMUNIQUÉ DE PRESSE Paris, le 22 juillet 2026 Ramsay Santé franchit de nouvelles étapes dans le cadre de l’élargissement envisagé de son flottant : succès du refinancement de sa dette senior et organisation d’un [...]
RAMSAY SANTE : Press Release - Refinancing new steps forward
22/07/2026
PRESS RELEASE Paris, 22 nd July 2026 New steps in connection with Ramsay Santé contemplated free-float expansion: Ramsay Santé successfully completes its senior debt refinancing and convenes a Capital Markets Day on 17 [...]
One Tulsa Physician Manages Hormone Therapy, Peptides and GLP-1 Weight Loss
22/07/2026
Results Medical Aesthetics & Wellness, a physician-led clinic in Tulsa, prescribes hormone replacement therapy only after comprehensive lab testing establishes a metabolic baseline. Laura Bilbruck, MD, an Oklahoma- [...]
Valneva publiera ses résultats financiers consolidés du premier semestre le 13 août 2026
22/07/2026
Lyon (France), le 22 juillet 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier semestre le jeudi 13 [...]
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
22/07/2026
Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The [...]
OKYO Pharma Announces Purchase of Shares by Chairman
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Ipsen - Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026
22/07/2026
DÉCLARATION RECTIFICATIVE Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026, publiée le 9 juillet 2026 Paris, le 22 juillet 2026 La présente [...]
Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026
22/07/2026
CORRECTIVE STATEMENT Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026, published on July 9, 2026 Paris, July 22, 2026 This corrective statement is [...]
Spryte Medical Completes INSYTE Trial Enrollment
22/07/2026
FDA-approved IDE study of the company’s neuro-optical coherence tomography nOCT™ Imaging System completes enrollment, representing a significant step toward regulatory submission for diagnostic use in intracranial [...]
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
22/07/2026
Revised transaction expands NexTel’s acquisition from JumpstartRx and NuevistraMed to Island 40 Group’s broader growth platform, adding health services, pharmaceutical access, lab testing, institutional partnerships, [...]
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing [...]
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
22/07/2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A [...]
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
22/07/2026
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop next-generation [...]

Pages